National Pharmacy Health & Leadership Alliance Verify a MemberMember Login
NPHLANational Pharmacy Health & Leadership Alliance
Apply for Membership

01MetabolicWhat Changed Today

What changed today in Metabolic: 20 trial updates, 9 new studies

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

By NPHLA IntelligencePublished Last updated Automated from official records

The signal

NPHLA tracked 29 new official records on this desk today: 20 trial updates, 9 new studies.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets[1]
  2. New trial registered: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver…[2]
  3. New trial registered: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished…[3]
  4. New trial registered: Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by…[4]
  5. New trial registered: SEMAFORCRANIO (SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in…)[5]
  6. New trial registered: A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight[6]
  7. New trial registered: TIRZE-PAP (Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative…)[7]
  8. New trial registered: Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients[8]
  9. New trial registered: TELWA (Probiotics in Obese Patients Treated With GLP-1 Receptor Agonists)[9]
  10. New trial registered: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or…[10]
  11. Plus 19 more official records today — browse the Metabolic desk feed for the full list.
  12. Also reported by MedPage Today: “New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says”.[11]
  13. Also reported by STAT: “STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial”.[12]
  14. Also reported by Pharmacy Times: “Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds”.[13]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
  3. [3]
  4. [4]
  5. [5]
  6. [6]
  7. [7]
  8. [8]
  9. [9]
  10. [10]
  11. [11]
    New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says

    News reportingMedPage TodayIndustry coverage — headline and link only

  12. [12]
  13. [13]
    Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds

    News reportingPharmacy TimesIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.